← The Wire
CBIONasdaq
CRESCENT BIOPHARMA, INC.
Pharmaceutical Preparations · E9 · CIK 1253689
Clinical-stage biotechnology company developing transformative cancer therapies, including bispecific antibodies and antibody drug conjugates
$494M
Market cap
$18.00
Last close
-3.0%
1D
+2.5%
5D
432K
Volume
Price · last 39 sessions+0.4%
May 4L $16.99 · H $21.47Jun 29
224
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
10-Q/A10-Q/AJun 22, 20268-KShareholder VoteJun 3, 20268-KResults of OperationsApr 29, 202610-Q10-QApr 29, 2026DEFA14ADEFA14AApr 21, 2026DEFA14ADEFA14AApr 21, 2026DEF 14ADEF 14AApr 21, 20268-KResults of OperationsFeb 26, 202610-K10-KFeb 26, 2026S-1S-1Jan 7, 2026SC 13D/ASC 13D/ADec 8, 20258-KMaterial Agreement · Equity IssuanceDec 4, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KExecutive Change · Results of OperationsJul 31, 202510-Q10-QJul 31, 20258-KAuditor Change · Change of ControlJun 18, 20258-KShareholder Vote · Reg FD DisclosureJun 6, 2025425425May 30, 20258-KCompany UpdateMay 30, 2025425425May 29, 202510-Q10-QMay 14, 2025425425Apr 29, 20258-KMaterial AgreementApr 29, 2025425425Apr 28, 2025425425Apr 3, 2025425425Apr 3, 2025425425Feb 28, 2025425425Feb 27, 2025425425Feb 25, 20258-KExecutive Change · Agreement TerminatedFeb 25, 2025S-4FORM-S-4Feb 18, 2025425425Feb 14, 20258-KMaterial AgreementFeb 14, 202510-K10-KFeb 13, 20258-KExecutive ChangeJan 31, 2025DEFA14ADEFA14AJan 13, 20258-KReg FD DisclosureJan 13, 20258-KDelisting NoticeDec 26, 2024SC 13GSC 13GNov 27, 202410-Q10-QNov 13, 2024DEFA14ADEFA14ANov 7, 20248-KReg FD DisclosureNov 7, 2024SC 13GSC 13GNov 6, 2024SC 13DGLYCOMIMETICS INCNov 4, 2024DEFA14ADEFA14AOct 29, 20248-KChange of Control · Executive ChangeOct 29, 202410-Q10-QAug 8, 20248-KExecutive Change · Exit / Disposal CostsJul 30, 20248-KDelisting NoticeJun 26, 20248-KExecutive ChangeJun 13, 20248-KReg FD DisclosureJun 4, 202410-Q10-QMay 9, 20248-KResults of Operations · Reg FD DisclosureMay 6, 20248-KBylaw Amendment · Shareholder VoteMay 2, 2024DEF 14ADEF 14AApr 1, 20248-KResults of OperationsMar 27, 202410-K10-KMar 27, 20248-KReg FD DisclosureMar 1, 20248-KMaterial AgreementJan 2, 20248-KResults of OperationsNov 3, 202310-Q10-QNov 3, 20238-KResults of OperationsAug 2, 202310-Q10-QAug 2, 20238-KShareholder VoteMay 22, 20238-KResults of OperationsMay 3, 202310-Q10-QMay 3, 20238-KMaterial AgreementApr 21, 2023DEF 14ADEF 14AApr 21, 20238-KResults of OperationsMar 29, 202310-K10-KMar 29, 20238-KReg FD DisclosureMar 10, 20238-KReg FD DisclosureMar 2, 20238-KExecutive ChangeFeb 21, 2023SC 13GSC 13GFeb 13, 202310-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KReg FD DisclosureOct 4, 202210-Q10-QAug 3, 20228-KResults of OperationsAug 3, 2022
Insider Activity
In the 90 days to Dec 4, 2025: 1 insider bought $18.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 4, 2025 | Harwin Peter EvanDirector,TenPercentOwner | Buy | 1,360,000 | $13.41 | $18.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance